Biotricity, الرعاية الصحية

Biotricity receives Health Canada clearance for Biotres

Biotricity Inc. (“Biotricityy”) announced its Health Canada approval for expansion into the US$1.56 billion Canadian Cardiology Devices market. Cardiovascular disease imposes a staggering US$21.2 billion annual cost in Canada alone, accounting for 11.6% of the entire Canadian health care cost.  Health Canada’s approval of Biotres, Biotricity’s flagship product, is a critical step in the Company’s quest to address the needs of more than 2.4 million Canadians living with heart disease and related conditions. This milestone achievement underscores Biotricity’s dedication to reshaping healthcare through innovation.

Recent Comments

لا توجد تعليقات للعرض.
Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
موقع YouTube
Consent to display content from - Youtube
فيميو
Consent to display content from - Vimeo
خرائط جوجل
Consent to display content from - Google
سبوتيفي
Consent to display content from - Spotify
Sound Cloud
Consent to display content from - Sound